These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 33761971)

  • 1. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy.
    Lodewijk I; Nunes SP; Henrique R; Jerónimo C; Dueñas M; Paramio JM
    Clin Epigenetics; 2021 Mar; 13(1):63. PubMed ID: 33761971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leveraging epigenetics to enhance the efficacy of immunotherapy.
    Licht JD; Bennett RL
    Clin Epigenetics; 2021 May; 13(1):115. PubMed ID: 34001289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging role of epigenetic therapeutics in immuno-oncology.
    Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
    Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
    Liu M; Zhou J; Chen Z; Cheng AS
    J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
    Flower KJ; Ghaem-Maghami S; Brown R
    Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic regulation of tumor immunity.
    Pang L; Zhou F; Liu Y; Ali H; Khan F; Heimberger AB; Chen P
    J Clin Invest; 2024 Jun; 134(12):. PubMed ID: 39133578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Perspective of Immunotherapy for Cancers.
    Keshari S; Barrodia P; Singh AK
    Cells; 2023 Jan; 12(3):. PubMed ID: 36766706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
    Cao J; Yan Q
    Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
    Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
    Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
    Loo Yau H; Ettayebi I; De Carvalho DD
    Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting galectins in T cell-based immunotherapy within tumor microenvironment.
    Jin QY; Li YS; Qiao XH; Yang JW; Guo XL
    Life Sci; 2021 Jul; 277():119426. PubMed ID: 33785342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy.
    Maio M; Covre A; Fratta E; Di Giacomo AM; Taverna P; Natali PG; Coral S; Sigalotti L
    Clin Cancer Res; 2015 Sep; 21(18):4040-7. PubMed ID: 26374074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Converting "cold" to "hot": epigenetics strategies to improve immune therapy effect by regulating tumor-associated immune suppressive cells.
    Tang Y; Cui G; Liu H; Han Y; Cai C; Feng Z; Shen H; Zeng S
    Cancer Commun (Lond); 2024 Jun; 44(6):601-636. PubMed ID: 38715348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.
    Pi YN; Qi WC; Xia BR; Lou G; Jin WL
    Front Immunol; 2021; 12():697083. PubMed ID: 34295338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
    Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
    Front Immunol; 2021; 12():652160. PubMed ID: 33859645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
    Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
    Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
    Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
    J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Turning Cold into Hot: Firing up the Tumor Microenvironment.
    Duan Q; Zhang H; Zheng J; Zhang L
    Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.